中国心力衰竭的宏观经济建模:干预策略研究
本研究基于全球疾病负担2021等数据,用健康增强宏观经济模型预测2025-35年中国心衰的宏观经济负担,并评估BNP筛查、强化降压和GDMT优化三种干预策略。结果显示心衰经济负担巨大,主要由劳动力损失驱动,三种干预均可降低总负担。
要点
- 2025-35年中国心衰累计经济负担达1001.1亿国际元,占GDP 0.26%。
- BNP筛查(25%覆盖)可节省78.5亿国际元,成本效益比0.49。
- 强化降压和GDMT优化分别节省27.5亿和17.0亿国际元,均具成本效益。
核心结论
- 心衰在中国造成巨大且持续增长的宏观经济负担,主要通过劳动力生产力损失实现。
- 可扩展且具成本效益的策略包括基层BNP筛查、补贴高血压控制和提升GDMT依从性,对遏制经济损失至关重要。
研究设计与样本
- 基于全球疾病负担2021、中国心血管协会注册和国家保险数据库数据,采用健康增强宏观经济模型预测2025-35年心衰负担。
- 评估三种干预:BNP筛查(≥40岁成人)、强化血压控制(高血压患者)、GDMT优化(射血分数降低的心衰)。
- 成本以2017年国际元(INT$)报告。
主要发现
- 2025-35年累计经济负担为1001.1亿INT$(95% UI: 733.4-1365.6亿),占GDP 0.26%(95% UI: 0.19%-0.34%),其中劳动力损失驱动占72.1%(95% UI: 64.4%-74.8%)。
- 干预措施降低总负担12.5%(95% UI: 10.4%-14.5%)。
- BNP筛查(25%覆盖)节省78.5亿INT$(95% UI: 62.8-94.1亿;降低8.10%;成本效益比0.49)。
- 强化血压控制节省27.5亿INT$(95% UI: 25.1-29.9亿;降低2.74%;成本效益比0.22),GDMT优化节省17.0亿INT$(95% UI: 12.8-22.4亿;降低1.70%;成本效益比0.48)。
临床怎么用
- 在基层医疗中推广BNP筛查(针对≥40岁成人)可作为心衰早期发现和减轻经济负担的策略。
- 对高血压患者实施强化血压控制并给予补贴,以及提升射血分数降低心衰患者的GDMT依从性,均具成本效益。
- 政策制定者可优先考虑上述可扩展的干预措施,以应对人口转型带来的心衰经济挑战。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: Heart failure (HF) imposes a growing public health and macroeconomic burden in low- and middle-income countries (LMICs), yet its long-term economic impact remains unquantified. China, characterized by rapid ageing and escalating cardiovascular risks, provides a critical setting to model HF economic implications. METHODS: Using data from the Global Burden of Disease Study 2021, China Cardiovascular Association Registry, and national insurance databases, HF macroeconomic burden (2025-35) was projected via a health-augmented macroeconomic model. Three interventions were evaluated: B-type natriuretic peptide (BNP) screening (adults ≥40 years), intensive blood pressure (BP) control (hypertensive patients), and guideline-directed medical therapy (GDMT) optimization for HF with reduced ejection fraction. Costs are reported in 2017 international dollars (INT$). RESULTS: By 2035, HF cases in China will reach 22.7 million [95% uncertainty interval (UI): 9.5-36.9 million], with an age-standardized prevalence of 760.65/100 000 (95% UI: 283.2-1340.8/100 000). The cumulative economic burden (2025-35) is INT$1001.1 billion (95% UI: 733.4-1365.6 billion), representing 0.26% of gross domestic product (95% UI: 0.19%-0.34%), driven by labour force attrition (72.1%; 95% UI: 64.4%-74.8%). Interventions reduced the total burden by 12.5% (95% UI: 10.4%-14.5%): BNP screening (25% coverage) saved INT$78.5 billion (95% UI: 62.8-94.1 billion; 8.10% reduction; cost-benefit ratio 0.49), Intensive BP control saved INT$27.5 billion (95% UI: 25.1-29.9 billion; 2.74% reduction; ratio 0.22), GDMT optimization saved INT$17.0 billion (95% UI: 12.8-22.4 billion; 1.70% reduction; ratio 0.48). CONCLUSIONS: HF imposes a substantial and increasing macroeconomic burden in China, largely through workforce productivity losses. Scalable, cost-effective strategies, including primary care-based BNP screening, subsidized hypertension control, and enhanced GDMT adherence, are essential to curb economic losses. These findings inform policy priorities for China and other LMICs confronting demographic transitions.
引用
- Wang, Zhou, Chai, et al. Heart failure in China: a macroeconomic modelling study of intervention strategies. Eur Heart J. 2026. PMID: 41355346. doi:10.1093/eurheartj/ehaf992
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。